Is FMC (FMC) Trading Below Fair Value On Its Sales?

FMC has seen its share price fall hard over recent years, which puts fresh focus on a simple question for anyone looking at the stock today. Is the current valuation really supported by the level of sales the business is generating?

• Over the past 5 years, FMC has fallen 85.9%, which puts the entire drop in market value up against what its revenue line can reasonably justify.
• The company’s ability to convert sales into reliable cash flow, and to fund its capital needs without stretching the balance sheet, now plays a crucial role in how investors think about what each dollar of revenue is worth.
• There is a second opinion on FMC worth weighing. See what analysts think FMC's shares could be worth.

The issue now is whether FMC’s current share price is appropriately aligned with its sales, given this track record and business profile.

If you are weighing FMC after such a steep 5 year decline, it can help to compare it with a wider set of beaten down stocks using a focused screen like 34 high quality undervalued stocks.

Is FMC Still Cheap on Sales?

P/S fits FMC because investors often look at chemical producers through their ability to turn each dollar of sales into an enduring franchise, even when earnings are choppy. On this lens, FMC trades on a P/S ratio of about 0.4x, compared with roughly 1.1x for the wider Chemicals industry and around 1.5x for its closer peer group. That is a steep gap in how the market values FMC’s revenue stream relative to comparable businesses.

The Fair Ratio model, which adjusts for FMC’s own mix of growth prospects, profitability profile, size and risk, points to a higher P/S than the share price currently implies. The current 0.4x multiple therefore sits below what this tailored framework would suggest for the stock and signals that each dollar of FMC revenue is being priced at a discount. To work out whether that gap reflects genuine mispricing or simply caution around future execution, you need to weigh this low headline multiple against balance sheet strength, cash generation and how cyclical the end markets feel to you. Explore the numbers behind FMC's P/S valuation.

The FMC Narrative: What Would Justify Today's Price?

FMC’s valuation question only really starts to make sense once you spell out what would need to change in its future profile for the current P/S gap to close. Simply Wall St Narratives on FMC set out those implied paths for growth, margins and earnings, and turn each one into a thesis about the business that can be tracked over time, all collected on the stock’s Community page.

Community views on FMC are split between those who see more upside in the repair story and those who think expectations already look full.

Bull case: 17% undervalued

"Ongoing cost transformation, including lower manufacturing costs for key products like Rynaxypyr and benefits from 2024-2025 restructuring, creates durable COGS reductions..."

Discover why this Narrative puts FMC at 17% undervalued.

Bear case: roughly fairly valued

"Mounting regulatory restrictions and outright bans on synthetic pesticides in major agricultural markets threaten to sharply curtail FMC's addressable market for core chemical products..."

Explore why this Narrative puts FMC at roughly fairly valued.

FMC's price is only one piece of the decision

Before you decide what FMC is worth to you, it helps to see where professional forecasts expect the business to be a few years from now and how that lines up with today’s multiples. Explore where analysts expect FMC to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com